BR112014012261A2 - tratamento de combinação de câncer - Google Patents

tratamento de combinação de câncer

Info

Publication number
BR112014012261A2
BR112014012261A2 BR112014012261A BR112014012261A BR112014012261A2 BR 112014012261 A2 BR112014012261 A2 BR 112014012261A2 BR 112014012261 A BR112014012261 A BR 112014012261A BR 112014012261 A BR112014012261 A BR 112014012261A BR 112014012261 A2 BR112014012261 A2 BR 112014012261A2
Authority
BR
Brazil
Prior art keywords
combinations
pharmaceutically acceptable
acceptable salt
treatment
cancer
Prior art date
Application number
BR112014012261A
Other languages
English (en)
Other versions
BR112014012261B1 (pt
Inventor
Robert Davies Barry
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014012261(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112014012261A2 publication Critical patent/BR112014012261A2/pt
Publication of BR112014012261B1 publication Critical patent/BR112014012261B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "tratamento de combinação de câncer". a presente invenção refere-se a uma combinação que compreende azd5363 ou um seu sal farmaceuticamente aceitável, e pelo menos um modulador de sinalização do receptor de androgênio selecionado a partir de mdv-3100 (também conhecido como enzalutamida), azd3514, abiraterona (ou um seu profármaco éster: por exemplo, acetato de abiraterona), e bicalutamida; ou um seu sal farmaceuticamente aceitável. cada uma dessas combinações pode ser útil no tratamento do câncer. a invenção também se refere a composições farmacêuticas que compreendem tais combinações, e também diz respeito a métodos de tratamento que compreendem a administração simultânea, sequencial ou separada de azd5363, ou um seu sal farmaceuticamente aceitável, com pelo menos um modulador da sinalização do receptor de androgênio, tal como descrito acima, a animais de sangue quente, tal como um ser humano, para o tratamento de câncer. a invenção também se refere a um kit que compreende tais combinações.
BR112014012261-0A 2011-11-30 2012-11-30 Combinação e uso de (s)-4-amino-n-(1-(4-clorofenil)-3- hidroxipropil)-1-(7h-pirrolo [2,3-d] pirimidin-4-il)piperidina-4- carboxamida com um modulador da sinalização do receptor de androgênio BR112014012261B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161564975P 2011-11-30 2011-11-30
US61/564,975 2011-11-30
PCT/GB2012/052969 WO2013079964A1 (en) 2011-11-30 2012-11-30 Combination treatment of cancer

Publications (2)

Publication Number Publication Date
BR112014012261A2 true BR112014012261A2 (pt) 2017-06-13
BR112014012261B1 BR112014012261B1 (pt) 2023-07-18

Family

ID=

Also Published As

Publication number Publication date
CN103945849A (zh) 2014-07-23
PL2785349T5 (pl) 2023-01-30
EP2785349B2 (en) 2022-11-09
IL232530B (en) 2018-07-31
RU2640485C2 (ru) 2018-01-09
AU2013205648A1 (en) 2013-06-13
ES2762250T5 (es) 2023-01-05
RU2014119713A (ru) 2016-01-27
EP2785349B1 (en) 2019-10-16
PL2785349T3 (pl) 2020-03-31
US20140329786A1 (en) 2014-11-06
SI2785349T2 (sl) 2023-01-31
CY1122624T1 (el) 2021-03-12
MX2014006547A (es) 2014-07-09
KR102035361B1 (ko) 2019-11-08
SI2785349T1 (sl) 2019-12-31
RS59493B2 (sr) 2023-02-28
PT2785349T (pt) 2019-12-11
WO2013079964A1 (en) 2013-06-06
HRP20191982T1 (hr) 2020-02-07
HRP20191982T4 (hr) 2023-01-06
CA2856646A1 (en) 2013-06-06
RS59493B1 (sr) 2019-12-31
HUE046667T2 (hu) 2020-03-30
DK2785349T3 (da) 2020-01-02
AU2012321110A1 (en) 2013-06-20
US20160151373A1 (en) 2016-06-02
EP2785349A1 (en) 2014-10-08
AU2012321110B2 (en) 2014-10-23
US9737540B2 (en) 2017-08-22
MY175800A (en) 2020-07-09
LT2785349T (lt) 2019-12-10
JP6309454B2 (ja) 2018-04-11
JP2015500225A (ja) 2015-01-05
ES2762250T3 (es) 2020-05-22
FI2785349T4 (fi) 2023-02-09
NZ625611A (en) 2016-10-28
HK1202253A1 (en) 2015-09-25
SG11201401471PA (en) 2014-08-28
IL232530A0 (en) 2014-06-30
CA2856646C (en) 2020-01-14
CN103945849B (zh) 2017-04-26
AU2013205648B2 (en) 2015-02-05
KR20140098799A (ko) 2014-08-08
MX367640B (es) 2019-08-29
DK2785349T4 (da) 2023-01-09

Similar Documents

Publication Publication Date Title
CY1122624T1 (el) Θεραπεια συνδυασμου του καρκινου
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
NZ726488A (en) Compositions and methods for transmucosal absorption
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
EA201590697A1 (ru) Производные кетамина
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
BR112015022196A2 (pt) composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112014015578A2 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
BR112019018185A2 (pt) composição para tratar uma doença de articulação humana, e, kit.
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
BR112012011316A2 (pt) tivozanib e temsirolimus em combinação
BR112013000296A2 (pt) agentes terapêuticos 976
BR112013033807A2 (pt) formulações pirroloquinolinil-pirrolidin-2,5-diona e métodos para sua preparação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023001581-9 PROTOCOLO 870230007647 EM 27/01/2023 14:54.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/11/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.